key: cord-0309408-bcu5n9gz
authors: Yao, Weitong; Ma, Danting; Wang, Haimin; Tang, Xiaojuan; Du, Chengzhi; Pan, Hong; Li, Chao; Lin, Hua; Farzan, Michael; Zhao, Jincun; Li, Yujun; Zhong, Guocai
title: Effect of SARS-CoV-2 spike mutations on animal ACE2 usage and in vitro neutralization sensitivity
date: 2021-08-05
journal: bioRxiv
DOI: 10.1101/2021.01.27.428353
sha: 9d421abeb5aaf1f5e05a0b52feae8a4a9f35ddb7
doc_id: 309408
cord_uid: bcu5n9gz

The emergence of SARS-CoV-2 variants poses greater challenges to the control of COVID-19 pandemic. Here, we parallelly investigated three important characteristics of seven SARS-CoV-2 variants, including two mink-associated variants, the B.1.617.1 variant, and the four WHO-designated variants of concerns (B.1.1.7, B.1.351, P.1, and B.1.617.2). We first investigated the ability of these variants to bind and use animal ACE2 orthologs as entry receptor. We found that, in contrast to a prototype variant, the B.1.1.7, B.1.351, and P.1 variants had significantly enhanced affinities to cattle, pig, and mouse ACE2 proteins, suggesting increased susceptibility of these species to these SARS-CoV-2 variants. We then evaluated in vitro neutralization sensitivity of these variants to four monoclonal antibodies in clinical use. We observed that all the variants were partially or completely resistant against at least one of the four tested antibodies, with B.1.351 and P.1 showing significant resistance to three of them. As ACE2-Ig is a broad-spectrum anti-SARS-CoV-2 drug candidate, we then evaluated in vitro neutralization sensitivity of these variants to eight ACE2-Ig constructs previously described in three different studies. All the SARS-CoV-2 variants were efficiently neutralized by these ACE2-Ig constructs. Interestingly, compared to the prototype variant, most tested variants including the variants of concern B.1.1.7, B.1.351, P.1, and B.1.617.2 showed significantly increased (up to ∼15-fold) neutralization sensitivity to ACE2-Ig constructs that are not heavily mutated in the spike-binding interface of the soluble ACE2 domain, suggesting that SARS-CoV-2 evolves toward better utilizing ACE2, and that ACE2-Ig is an attractive drug candidate for coping with SARS-CoV-2 mutations.

respectively, in a bio-layer interferometry (BLI)-based assay to measure the interaction kinetics 141 of fifty-six RBD-ACE2 pairs (Figure 3 and Table 2 ). When the RBD of early SARS-CoV-2 142 isolate WHU01 was tested against different ACE2 proteins, strong interactions were observed 143 for human, cattle, pig, cat, and rabbit ACE2 proteins, with human ACE2 showing the highest 144 affinity to this RBD. No any binding signal was detected for mouse ACE2 (Figure 3H) . We 145 then compared the kinetics data of each RBD variants to the data of the WHU01 variant. We 146 observed that the Y453F mutation increased RBD affinity to human ACE2 by ~4.7-fold 147 ( Figure 3A and Table 2 ), consistent with a very recent report 42 . In addition, the B.1.617.2 148 RBD but not the B.1.617.1 RBD was also found with >2-fold higher affinity to human ACE2 149 ( Figure 3A and Table 2 ), consistent with the fast spreading of this variant across the world.

N501Y mutation enhances RBD affinity to most of the tested ACE2 proteins, especially 151 cattle and pig ACE2 proteins 152 In the case of the B.1.1.7 RBD which has a N501Y signature mutation, we observed 2.9-fold 153 increase in the RBD affinity to human ACE2 ( Figure 3A and Table 2 ). This is consistent with 154 the binding data from other reports and the increased infectivity of the B.1.1.7 variant [39] [40] [41] [43] [44] [45] . 155 Structural studies show that the Tyr501 residue of the B.1.1.7 RBD inserts into a cavity at the 156 binding interface and forms a perpendicular π-π stacking interaction with the Tyr41residue of C). The B.1.617.1 RBD showed complete loss of interaction with LY-CoV555 ( Figure 6B ). 214 Consistent with the neutralization data, the B.1.617.2 RBD showed significantly decreased 215 affinity to LY-Cov555, but increased affinity to REGN10933 (Figure 5L, 6B, and 6C) . These 216 data demonstrate that SARS-CoV-2 variants could easily develop resistance to neutralization 217 antibodies or even antibody cocktails in clinical use, highlighting the necessity of developing 218 broad-spectrum anti-coronavirus agents. Ig-Glasgow-311, ACE2-Ig-Glasgow-313) 47 . Because we previously found that the CLD 230 domain of human ACE2 has an ~20-fold contribution to ACE2-Ig's neutralization activity 231 against SARS-CoV-2 pseudoviruses 14 , we used CLD-containing soluble ACE2 domains for all 232 the constructs tested in this study. We got three interesting findings here (Figure 7) . First, all 233 the twelve SARS-CoV-2 variants were potently neutralized by all the eight ACE2-Ig constructs, 234 demonstrating that ACE2-Ig is a broad-spectrum anti-SARS-CoV-2 agent. Second, the mink-235 associated variant Y453F-F486L-N501T showed partial resistance to ACE2-Ig-Glasgow-310 236 and ACE2-Ig-Glasgow-313, but clearly increased sensitivity to ACE2-Ig-v1, ACE2-Ig-v1.1 237 and ACE2-Ig-v3, the constructs that are not heavily mutated in the spike-binding interface of the soluble ACE2 domain (Figure 7A-C, F, H) . These data suggest that extensively mutating 239 the ACE2 residues near the RBD-binding interface should be avoided. increased (up to ~15-fold) neutralization sensitivity to ACE2-Ig-v1, ACE2-Ig-v1.1 and ACE2-244 Ig-v3, the constructs that carry a wild-type or a D30E-mutated ACE2 domain (Figure 7A -C).

In this study, we parallelly investigated multiple circulating SARS-CoV-2 variants, including 247 two mink-associated variants, the B.1.258 and B.1.617 variants, and the VOCs B.1.1.7, B.1.351, 248 and P.1. As receptor usage is a critical determinant for the host range of coronaviruses, we 249 first investigated the ability of these variants to utilize animal orthologs of ACE2 as an entry 250 receptor. We found that, in contrast to an early isolate WHU01, the VOCs B.1.351, and P.1 251 were able to bind and use mouse ACE2 for entry, suggesting that these variants may have In addition, we found that multiple variants, especially the VOCs B.1.1.7, B.1.351, and P.1, 260 have significantly increased affinity to cattle and pig ACE2 proteins (Figure 3 and This could further enable these variants to efficiently use cattle and pig ACE2 proteins. These isolate WHU01, all the tested variants carrying mutations in the RBD region showed partial or 285 fully escape from at least one and up to three of the four tested antibodies (Figure 5 and 6) , 286 none of the variants escaped ACE2-Ig (Figure 7) , a broad-spectrum anti-SARS-CoV-2 drug candidate. More importantly, we found that most of the tested SARS-CoV-2 variants had 288 increased (up to ~15-fold) sensitivity to ACE2-Ig constructs that carry a wild-type or a single-289 point-mutated ACE2 domain ( Figure 7A-B) . This might be explained by increased affinity of 290 SARS-CoV-2 variant to human ACE2 or increased accessibility of the RBDs of SARS-CoV-2 291 variants. Indeed, we observed a 4.7-fold, 2.9-fold, 2.0-fold and 1.6-fold increase in the affinity 292 of human ACE2 to the RBDs of the mink-associated Y453F variant, the B. suggest that SARS-CoV-2 was evolving toward better utilization of ACE2 as a receptor, either 298 through increasing RBD affinity to ACE2, or through better exposure of its RBDs, or through 299 both. It further indicates that ACE2 is still likely an essential receptor for SARS-CoV-2. ACE2 300 also serves as a cellular receptor for a number of other coronaviruses, including SARS-CoV, 301 HCoV-NL63, Pangolin-CoV-2020, Bat-CoV RaTG13, and some other SARS-like CoVs found 302 in bats 14,16,59 . ACE2-Ig is therefore a promising broadly anti-coronavirus drug candidate that 303 might be used to treat and prevent infection of these diverse coronaviruses and their variants.

It might also be a good alternative anti-SARS-CoV-2 agent for the populations who are not 305 responsive to, or don't have access to any prophylactic vaccines.

There are a couple of limitations of the current study. SARS-CoV-2 spike-pseudotyped 307 reporter viruses, instead of live viruses, were used to study virus-ACE2 interaction and 308 neutralization sensitivity of multiple circulating SARS-CoV-2 variants. It is difficult to obtain 309 or access live SARS-CoV-2 variants, and even more difficult to simultaneously obtain multiple method in the field for studying various enveloped viruses, such as HIV 60,61 , influenza virus 62- Table 2 . Table 3 . 

ACE2-Ig-v1, ACE2-Ig-v1.1, ACE2-Ig-v3

A-C) ref.14 , one from Chan et al (ACE2-Ig-Chan-696 v2

D) ref.46 ; and four from Glasgow et al (ACE2-Ig-Glasgow-293

HeLa-hACE2 cells were 699 infected with each of the twelve pseudoviruses in the presence of the indicated ACE2-Ig 700 proteins at the indicated concentrations. Viral entry was measured by luciferase reporter 701 expression at 48 hours post infection. Luminescence values observed at each concentration 702 were divided by the values observed at concentration zero to calculate percentage-of-infection 703 (Infection%) values. Data shown are representative of three independent experiments 704 performed by two different people with similar results, and data points represent mean ± s

 Tables 1-3   Table 1 . Species and accession numbers of the amino-acid sequences of the eight ACE2 orthologs investigated in this study.